For the roughly 135 Australians diagnosed each year with a rare, mutation-driven brain cancer, medicine has long offered only blunt remedies against a disease that dismantles lives in their earliest chapters. As of August 1st, a new chapter opens: vorasidenib, the first targeted treatment in twenty years for IDH-mutant astrocytoma, has been added to Australia's Pharmaceutical Benefits Scheme, collapsing a monthly cost of $28,000 into something ordinary people can afford. It is not a cure — the disease remains incurable — but it is a meaningful shift in what it means to live with an illness tha
Rare brain cancer treatment now affordable via PBS subsidy
Patients with this rare, incurable brain cancer face seizures, cognitive changes, physical disability, and loss of independence; the disease typically strikes people in their 20s and 30s.